Abstract: Objective To explore the effects of sacubitril/valsartan combined with bisoprolol on serum inflammatory factors highsensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6), and tumor necrosis factor-α(TNF-α) and cardiac function in patients with coronary heart disease(CHD) complicated by chronic heart failure(CHF). Methods A total of 160 patients with CHD and CHF, classified as New York Heart Association functional class Ⅱ-Ⅲ, admitted to the Department of Cardiology of Shulan(Quzhou) Hospital from February 2022 to February 2024 were selected. They were divided into two groups using a random number table method, with 80 patients in each group. The control group was administered bisoprolol, while the intervention group received sacubitril/valsartan combined with bisoprolol. The treatment course lasted 3 months in both groups, with follow-up conducted up to 6 months. The differences in clinical efficacy, serum inflammatory factors, and cardiac function indices were compared between the two groups. Results The total effective rate of the intervention group was 90.00%, which was higher than the 75.00% in the control group(P< 0.05). At 3 months post-treatment and at the 6-month follow-up, the left ventricular ejection fraction and cardiac output in the intervention group were significantly higher than those in the control group, while the left ventricular end-systolic diameter was shorter(P< 0.05). The levels of TNF-α, IL-6, hs-CRP, N-terminal pro-B-type natriuretic peptide, plasma viscosity, whole blood viscosity, and hematocrit in the intervention group were also significantly lower than those in the control group(P< 0.05). Conclusion Sacubitril/valsartan combined with bisoprolol in the treatment of CHD complicated by CHF can not only markedly improve clinical efficacy, but also effectively reduce serum inflammatory factor levels and enhance cardiac function.